Systematic review of non-surgical treatments for early Dupuytren’s disease by Catherine Ball et al.
RESEARCH ARTICLE Open Access
Systematic review of non-surgical
treatments for early Dupuytren’s disease
Catherine Ball* , David Izadi, Liaquat Suleman Verjee, James Chan and Jagdeep Nanchahal
Abstract
Background: Dupuytren’s disease is a common fibrotic disorder of the palm characterized by the development of
progressive flexion deformities in the digits, leading to significant functional impairment. Surgical excision remains
the most common treatment. However, this is only indicated in patients with established contractures rather than
those with early disease. Early disease is generally characterized by the presence of palmar nodules with limited or
no contracture of the fingers. The ideal treatment would be directed at patients with early progressive disease to
prevent future deterioration. Various non-surgical treatment modalities have been described but there is currently
no systematic assessment of the role and efficacy of these treatments in patients with early disease.
Methods: Using a PICOS analysis we reviewed publications of studies of patients with early disease who had
received physical therapies, pharmacological treatment, or radiotherapy. Following PRISMA guidelines titles and
abstract were screened using predefined criteria to identify those reporting outcomes specifically relating to the
treatment of early disease. In the absence of a definition of early disease studies were included if early DD was
described clinically, with digital contractures not exceeding 30°, Tubiana grades N to 1, and which reported
identifiable data. Studies were excluded if data for early DD patients could not be extracted for analysis.
Results: In this systematic review, 26 studies were identified and analyzed to evaluate the effect of pharmacological
therapy (n = 11), physical therapy (n = 5) and radiotherapy (n = 10) on early Dupuytren’s disease. The studies
comprised 20 case series, 1 cohort study with the remainder reporting case studies. All publications were graded
level of evidence 4 or 5 assessed using the Oxford Centre for Evidence Based Medicine grading. Narrative
descriptions of the data are presented.
Conclusions: Physical therapies were the most robustly assessed, using objective measures but the studies were
under powered, providing insufficient evidence of efficacy. Intralesional steroid injection and radiotherapy appeared
to lead to softening of nodules and to retard disease progression but lacked rigorous evaluation and studies were
poorly designed. There is an urgent need for adequately powered double blinded randomized trials for this
common disorder which affects 4 % of the population.
Trial registration: The protocol was registered (CRD42015008986 16 November 2015) with the PROSPERO
international prospective register of systematic reviews.
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Background
Dupuytren’s disease (DD) is a common fibroproliferative
disorder of the hand affecting approximately 4 % of the
general UK and US populations [1, 2]. The prevalence of
DD in the general population increases with age and in
a recent systematic review was estimated as 12 % in
those aged 55 years, rising to 29 % in those aged 75 years
in the general population in western countries [3]. The
classic description of disease progression is the initial
appearance of nodules, with subsequent formation of
cords. This is followed by a final stage as the cords ma-
ture and irreversible digital contractures develop, result-
ing in significant impairment of hand function [4].
However disease progression is not inevitable, with only
30-50 % going on to develop progressive flexion
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deformities [5, 6] and that the course of DD may fluctu-
ate over time [7].
One of the earliest classifications of Dupuytren’s
disease according to the histological appearance using
optical microscopy [8] described 3 stages: proliferative,
involutional and residual. Further sophistication was
added by correlating histological appearance with the
clinical findings and ultrastructural features [4]. This
was extended by Lam [9] using electron microscopy to
include the relative proportion of type III collagen based
on the finding that earlier lesions have a higher propor-
tion of type III collagen, which changes to a greater pro-
portion of type I collagen at later stages of the disease.
One of the few groups to study tissues collected at all
clinical stages of the disease also classified the disorder
into 3 stages [10]:
I. Early disease. Specimens comprised nodules from
patients with no digital contracture. These showed
proliferating spindle shaped cells surrounded by fine
granulofibrillary material although there was no
increased collagen deposition in the nodule.
II. Active disease. Clinically these patients presented
with palmar thickening and associated joint
contracture, with the contracture noted by the
patient as occurring on average over 3 years. The
nodules comprised mainly of myofibroblasts, with
very little intervening collagen. The nodules were
associated with cords, which were relatively
acellular.
III. Advanced disease. These patients had progressive
joint contracture for more than 3 years. Microscopic
examination revealed relatively few cells that were
elongated and embedded in stroma comprising a
large amount of mature collagen fibers.
A study of surgically excised specimens from patients
with digits flexed to 30° or greater and with functional
impairment of the hand showed that even in this group
nodules comprising aggregates mainly of myofibroblasts
with interspersed inflammatory cells are embedded
within the cords and anatomically lie adjacent to the
flexed joint [11]. Furthermore, patients with more ad-
vanced deformities were less likely to have identifiable
nodules, corresponding to the advanced stage described
by Chiu et al. [10].
A number of clinical grading and staging systems that
record the presence of palmar nodules, cords and the
degree of digital flexion to reflect disease severity have
been proposed [8, 10, 12–19] (Table 1).
Currently there is no formal clinical definition of
early disease and no widely accepted treatment. Ex-
pert opinion suggests that non-surgical treatments for
DD are not effective in reversing or retarding disease
progression [20] and are generally considered ineffect-
ive [21]. However, the evidence has not been system-
atically evaluated [22].
The mainstay of treatment for patients with estab-
lished flexion deformities is surgery. Surgery is consid-
ered if a finger has lost 30° of metacarpophalangeal joint
or any proximal interphalangeal joint extension [23].
Surgery is not advocated in early DD except when it is
associated with persistent pain, especially at night or in
the rare circumstances where a trigger finger requiring
surgical release necessitates access to the A1 pulley deep
to a DD nodule [24]. Furthermore, surgery undertaken
during the more cellular, proliferative stage of the dis-
ease is considered to be associated with a higher rate of
recurrence [25].
Methods
A systematic review was performed to determine the
role and efficacy of non-surgical treatments for early
DD and to provide an evidence base for the mana-
gement of these patients. The search strategy and
search terms were based on a Participants, Interven-
tion, Comparison, Outcomes and Study (PICOS) de-
sign [26] (Additional file 1). A literature search was
performed using controlled subject headings and free text
terms for “Dupuytren’s disease” and “non-surgical therap-
ies”. A broad range of terms covering pharmacological
therapies, radiotherapy and physical therapies were used
to formulate a comprehensive and inclusive search
strategy for non-surgical therapies for early DD. The
protocol was registered (CRD42015008986) with the
PROSPERO international prospective register of sys-
tematic reviews [27].
Inclusion and exclusion criteria
Studies evaluating non-surgical treatment of adults with
early DD where outcomes were monitored using patient
reported outcome measures, physical measures, clinical
assessment and clinical observation were included. Ran-
domized and non-randomized controlled clinical trials,
prospective and retrospective case series, case studies,
conference abstracts and letters were eligible for inclu-
sion. Studies comprising all stages of DD were scruti-
nized to extract data pertaining to early DD where
possible. Early disease was defined as a baseline contrac-
ture of 30° or less at each affected digital joint or as a
grade or description of palmar involvement with digital
contracture of 30° or less.
Studies involving 2 or more digits on 1 hand were ex-
cluded if any digital contracture exceeded 30° indicating
more advanced disease in the hand. Studies reporting
treatment of later stage DD, recurrent DD or postopera-
tive DD were excluded. Patients within studies who had
received treatment previously for DD in the pertinent
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Table 1 Clinical staging and grading systems for Dupuytren’s disease
Author Iselin (1951) [13] Shaw (1951) [57] Steinberg
(1951) [18]
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hand were excluded. There was no language restriction
for eligibility for inclusion. There was no restriction
regarding duration of post intervention monitoring
(Additional file 2).
Search methods and identification of studies
Ovid Medline and Embase databases were searched from
inception to October 2015. A total of 930 references, fol-
lowing removal of duplicates by both electronic and
manual screening, were downloaded into a bibliographic
software package (EndNote ×7). Three additional studies
were identified from a personal bibliography. In total 97
studies were identified by title/abstract review applying
the eligibility criteria after independent review by 2 au-
thors (CB and DI or LV), resulting in 26 studies meeting
the inclusion criteria (Fig. 1).
Where necessary, consensus was achieved by review-
ing the full text by a fourth author (JN). Full texts of all
studies were further reviewed by the same 2 authors (CB
and DI or LV) to identify data specifically relating to
early DD (Additional file 3).
Data collection and analysis
Data on study design, intervention, study dates, criteria
used to identify early DD, number of early DD patients,
number of total cohort, outcomes measured, baseline
data and results were collected and tabulated on an
Excel (Microsoft, Seattle) spreadsheet. Adverse events
when reported were noted. Due to the heterogeneity of
the studies and variability in the techniques used to
analyse and report the data, pooled analysis or meta-
analysis were not warranted and narrative descriptions
of the data are presented. The quality of studies was
assessed using the Oxford Centre for Evidence Based
Medicine (OCEBM) levels of evidence criteria [28]. Risk
of bias was assessed using GRADE guidelines, Cochrane
Handbook for Systematic Reviews [29].
Results
Of the 26 studies that met the inclusion criteria, 11
pertained to pharmacological treatment [18, 30–39], 5
to physical therapies [40–44] and 10 to radiotherapy
[14, 45–53]. All included studies were observational
Fig. 1 PRISMA flow diagram
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and graded OCEBM level 4 or 5. The risk of bias for
all studies was high. Three studies declared no con-
flict of interest [42, 51] or financial gain [31], one
study declared grant funding from the Squibb Insti-
tute of Medical Research [18] and one study disclosed
that cortisone was supplied by the National Research
Council of Canada [30].
The studies comprised 20 case series [14, 18, 31, 33, 34,
36, 37, 40–42, 44–53], 6 case studies [30, 32, 35, 39, 43]
with 2 by 1 author [30], and 1 cohort study [38]. Only 4
publications described results for cohorts comprising ex-
clusively of early DD patients [31, 46, 48, 49]. The
remaining studies included early DD patients within co-
horts of patients with more advanced disease.
Pharmacological therapy
Eleven studies related to pharmacological therapies
(Table 2), including steroids [30–34], vitamin E [18, 35, 36],




Three studies reported the use of intranodular [31],
intralesional [33] or immediately below the nodule
[34] steroid injection. In an early study [34] 2 cases
of early DD defined as Meyerding Stage 0 within a
larger cohort of DD patients were administered
hydrocortisone injections ‘immediately below the nod-
ule’. Each was injected with 5 and 12mgs respectively
once a week for 4 weeks. Outcomes were assessed
clinically as defined by ‘nodule disappearance’ and re-
sults for both cases described as ‘good’. The follow-up
period was not stated.
The rationale for intranodular and intralesional steroid
injections was based on early clinical and experimental
studies examining the inhibitory effect on connective tis-
sue development [33], and subsequently on degradation
of mature collagen in hypertrophic scars [31]. All re-
ported clinically observed measures as outcomes.
Zachariae [33] injected hydrocortisone acetate in 9 pa-
tients (9 hands) with early DD as defined by palmar fi-
brosis with no contracture, or a total contracture of all
joints of a digit of 30° or less. Six patients received a
total of 3 injections of 25 mg, 1 patient 2 injections of
50 mg, 1 patient received 2 injections of 10 mg followed
by 1 injection of 25 mg, and 1 patient was injected twice
with 25 mg. All injections were administered at 2–3
weekly intervals over a 2–5 week period. The follow-up
period ranged from 2 to 24 months. Outcome was
assessed clinically and fibrosis reported subjectively to
be ‘diminished’, ‘slightly diminished’ or ‘softened’ in all
cases, with resolution of pain in both cases describing
pain at baseline. Recurrence after 14 months was
reported in the patient who received two 10 mg and one
25 mg injection.
A larger and more recent case series comprised a
retrospective review of 63 patients (75 hands) with early
DD defined as a flexion contracture of less than 15° at
the metacarpophalangeal (MCP) joint and no contrac-
ture at the proximal interphalangeal (PIP) joint at base-
line [31]. All patients were treated using a series of
intranodular injections with triamcinolone acetonide.
The dose per patient ranged between 80-120 mg at each
visit at 6 weekly intervals and an average of 3.2 injec-
tions at each site. After a period of 6 months, 3 further
injections were given if required. The follow-up period
ranged from 30 months to 27 years. The outcome meas-
ure used was clinician rated ease of injection. Seventy
three hands (62 patients) were reported as having nod-
ules described ‘easier to inject’ and to show 60–80 %
regression as defined by the nodules being ‘flatter’. There
was no change in digital contracture in this group.
However, the remaining patient with bilateral disease re-
quired surgery. Disease reactivation requiring one or
more further injections was observed in 50 % of patients
1 to 3 years after the last injection. Adverse events were
reported for 50 % of patients, including transient depig-
mentation or subcutaneous atrophy at the injection site,
all of which were described as having resolved within
6 months of the last injection.
Topical steroids
Topical application of steroid cream has been reported
to suppress local immunological inflammatory change
[54]. One patient with early DD, defined as a painful fi-
brous cord with no restriction of digital extension, was
treated with topical application of clobetasol cream twice
daily and 0.1 % tretinoin cream once daily [32]. At
3 months, pain had resolved and the contracture was
described as ‘shrinking’. By 9 months the hand was
reported as ‘normal’ and there was no recurrence at
2 years.
Oral steroids
There is only 1 case report of a patient treated with oral
steroids for early DD. The patient was described as hav-
ing bilateral early DD with restriction of digital exten-
sion of the little and ring fingers of the left hand by 1
and 2 centimeters respectively, and minimal changes
with no extension restriction in the right hand. He was
treated with a total oral dose of 200 mg cortisone acetate
daily for 3 weeks but there was no clinically observable
change [30].
Intramuscular steroids
A patient with bilateral early DD defined by lack of full
digital extension by 0.5 cm treated with 200 mg of
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Study type Level of evidence (OCEBM)
Prospective (P) Retrospective
(R) Not stated (N)
Outcome measure Results Recurrence Adverse events




11 (16) 1 (2) Case study 5 (N) Clinical observation
of nodules, extension
deficit
0 1 0 Not reported Not reported
Oral 1 (2) Case study 5 (N) Clinical observation
of palmar fascia
0 1 0 Not reported Not reported
Ketchum (2000) [31],
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2 1 Case study 5 (N) Contracture shrinkage 1 0 0 None at 2 years Not reported
Zachariae (1955) [33],
Injection
11 (11) 9 (9) Case series 4 (N) Fibrosis diminished
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9 0 0 1 at 14 months Not reported
Coste (1953) [34],
Injection
9 (13) 2 (2) Case series 4 (N) Clinical observation
of nodules, extension
deficit
2 0 0 Not reported Not reported
Vitamin E (oral)
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98 74 Case series 4 (N) Clinically observed
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3 at 2 years, 2 after
3 years)










63 22 Cohort study 4 (N) Clinical observation
of palm thickening,
tension and trembling












Table 2 Summary of results of pharmacological treatment (Continued)
Topical aminosyn 4 4 0 0
Ultrasound 6 4 2 0
Yildiz (2004) [39],
Hyperbaric oxygen
1 1 Case study 5 (N) Extension deficit,
clinical observation
1 0 0 None at 1 year No adverse effects.
Summary of results of pharmacological treatment from each study, including the number of patients with Dupuytren’s disease in the total cohort in each study, the number of patients with early disease within the
total cohort, study type and design, level of evidence according to the Oxford Centre for Evidence Based Medicine (OCEBM) criteria, the outcome measure used and results. The number of hands (in brackets) is stated












cortisone daily intramuscularly for 2 weeks also showed
no improvement [30].
Vitamin E
Three studies reported use of vitamin E [18, 35, 36].
Based on clinical findings that daily administration of
200 mg of ephynal for 20 weeks resulted in a decrease in
palmar fibrosis and an increase in digital extension in 13
patients (22 hands) affected to varying degrees by DD
and who had not previously had surgery [55], it was hy-
pothesized [18] that vitamin E downregulates fibroblast
activity. Six patients with early DD defined as grade 1
(fibrosis of the palmar fascia without contractures), were
treated with 300 mg of mixed natural tocopherols for up
to 7 months. Four patients were reported to be ‘cured’
and 2 ‘improved’ [18].
A study of 63 hands [36] with early DD defined as
thickening of the palmar fascia only or digital flexion de-
formity of 30° or less at either the MCP or interphalan-
geal joints reported on the efficacy of systematic vitamin
E. Oral doses of 100 mg of tocopherol acetate were ad-
ministered twice daily for a minimum of 3 months. No
rationale for treatment was described. Plaster cast molds
were used to record the deformity at baseline and com-
pared with the presenting deformity at follow up. No
clinically observable improvement was reported in 60
hands, and deterioration occurred in 3 hands. Toxic ef-
fects of treatment were not seen. In a case study Reilly
[35] described developing early DD with a small hard
nodule in his right palm, with subsequent digital flexion,
and similarly in the left hand 3 years later. He reported
self-administration of 400 mg oral alpha tocopherol suc-
cinate daily for 14 years with no effect on either of his
hands, eventually requiring surgery for both hands.
Other
A cohort study [38] applied topical aminosyn with (n = 22)
or without ulltraphonophoresis (ultrasound) (n = 6), or
ultrasound only (n = 4) to patients with early DD defined as
palmar thickening and tension, pain and trembling being
grade 1 on a grading scale of 1 to 3. An application of 1–2
centimeter thickness aminosyn with or without ultrasound,
or ultrasound alone was administered 5 days a week
for 3–4 min for a total of 12-18 procedures. Out-
comes were measured by clinical examination and pa-
tient reported softening and reduced thickening of
contractures at the end of treatment and were catego-
rized in 5 classifications from ‘clinically healthy’ to
‘no improvement’. Across all groups, 29 of the 32 pa-
tients improved and 3 showed no change.
Furazolidon (20 mg) was injected into the affected pal-
mar aponeurosis of 74 patients with early disease [37].
Treatment was stated to be based on the anti-fibrotic ef-
fect of the drug. Early disease was defined as Stages 1
and 2 according to the presence of nodules and cords
with digital joint contractures up to 30°. Patients were
given a total of 5–7 injections at 10–14 day intervals.
Outcomes were defined by clinically observed reduction
of contracture and softened nodules and cords and cate-
gorized as ‘good’, ‘satisfactory’ or unsatisfactory’. On
examination at 1–5 years after injection, 70 patients
were classified as ‘good’ and 4 as ‘satisfactory’. Of the
total cohort of 98 patients, 18 reported minor hand
swelling and raised temperature after the first injection.
No systemic toxic effects were found.
Hyperbaric oxygen was administered to a single pa-
tient with early disease described as an isolated palmar
cord with no nodule and 10° MCP joint extension deficit
[39]. The authors based the treatment on the premise
that high tissue oxygenation could reverse local ischemia
that they postulated could be associated with DD. Fol-
lowing 40 sessions totaling 60 h of treatment over
2 months, the palmar cord was reported to be no longer
visible and full extension of the joint was achieved, with
no adverse effects of treatment.
Physical therapy
Five studies reported physical therapy for the treat-
ment for early DD, including ultrasound [40], splinting
[41, 42], frictional massage [43] and heat treatment with
joint stretching [44] (Table 3).
A series of 3 patients (4 hands, 6 digits) with early DD
[40] from a larger cohort of 8 patients were treated using
low intensity therapeutic ultrasound combined with
physical mobilization and joint stretching. The rationale
for use was based on the premise that treatment with
ultrasound leads to softening and increased extensibility
of the fibrous tissue. Outcomes were assessed using ob-
jective physical measures and clinical examination. Ac-
tive digital joint extension was measured in degrees
using a goniometer, hand span in centimeters, power
grip strength was measured in pounds, and palmar
consistency assessed by clinical examination. Patients
were treated with ultrasound for between 4 and 10 min
weekly over 5 to 8 weeks until no further improvement
was observed. Exercise and stretching followed each
ultrasound treatment. Two patients with limitations in
digital extension (4 fingers) were reported as having im-
proved between 5 to 23°. Palmar tissue in both hands of
a patient with palmar thickening and no digital limita-
tion was considered to have become softer. Hand span
increased in 2 patients by 0.7 and 2.4 centimeters and
remained unchanged in both hands of the third patient.
Grip strength improved in all 3 patients by between 3
and 6.5 pounds.
Two studies reported on the use of night splints with
patients with early DD [41, 42], with outcomes compar-
ing the degree of active individual digital joint extension
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Study type Level of evidence (OCEBM)
Prospective (P) Retrospective
(R) Not stated (N)
Outcome measure Results Recurrence Adverse
eventsImproved No change Deteriorated
Markham (1980) [40],
Ultrasound
8 (9 hands) 3 (4 hands) Case series 4 (P) Digital joint extension
in degrees (n= 4)









Hand span (n = 4) 2 2
Grip strength (n = 4) 4
Ball (2002) [41],
Splinting






0 None at 2 years Not reported
Larocerie-Salgado,
(2012) [42], Splinting
13 (13 hands) 2 Case series 4 (P) Digital joint extension
in degrees








0 0 Not reported Not reported
(Control hand) 0 0 1 hand (2 digits)
Onat (2013) [44], Heat,
splinting, stretching
3 2 Case series 5 (N) Degrees of digital
motion
2 0 0 Not reported Not reported
Summary of results of physical therapy treatment for each study, including the number of patients with Dupuytren’s disease in the total cohort in each study, the number of patients with early disease within the total
cohort, study type and design, and level of evidence according to the Oxford Centre for Evidence Based Medicine (OCEBM) criteria, the outcome measure used and results. The number of hands (in brackets) is stated












measured using a goniometer before and after treatment.
The studies were based on the premise that low load
tension promotes tissue remodeling [42] as a result of
increased matrix metalloproteinase activity [56]. A pro-
spective study of 5 patients (6 digits) with early DD
treated with thermoplastic palmar based finger extension
splints worn at night reported increased active digital ex-
tension in 4 patients (5 digits) and no change in 1 pa-
tient. Improvement ranged from 2 to 12° at follow-up
between 4 and 24 months from baseline [41]. A more re-
cent study reported the results of 2 early DD patients
with PIP joint contractures in a larger cohort of 13 DD
patients [42]. Both patients treated using a combination
of extension splinting, stretching exercises and fric-
tion massage improved by 20° at follow-up at 5 and
22 months respectively. Two patients in a study of
physical therapy received paraffin bath heat treatment
combined with joint stretches, ultrasound and splinting
[44]. Early disease was defined by degrees of digital exten-
sion. Following 15 therapy sessions improvements of 10°
were reported for both patients.
A case study of a patient with early DD compared the
results of treating the ring and little fingers of 1 hand
using frictional massage and stretching, with the contra-
lateral hand treated using stretching alone [43]. Early
DD was identified by the presence of palmar nodules in
both hands with a cord of DD in 1 hand but no flexion
deformity; however, the ability to actively hyperextend
the affected digits was limited in both hands. Treatment
was based on the supposition that cross-frictional mas-
sage may soften contractile structures, although the
exact mechanism is subject to debate. Each hand was
treated with 2 min of stretching with or without add-
itional friction massage 3 times weekly for 8 weeks. Ac-
tive digital hyperextension was measured in millimeters.
Increases of 1 mm and 13 mm were reported at
4 months in the ring and little fingers, respectively, in
the combined massage and stretching treatment hand as
compared to baseline. In contrast, decreases of 2 mm
and 3 mm respectively were reported at 4 months in the
hand treated by stretching alone. Comparison with pre-
treatment photographs showed a decrease in contracted
palmar skin of the left hand. At 8 weeks there was no
change noted in the area of the nodules as assessed by
ultrasound scan.
Radiotherapy
Ten publications reporting outcomes of patients with
early DD treated with radiotherapy met the inclusion
criteria, six from Germany [14, 45–49] with the remain-
der from Italy [50], Australia [51] and 2 from the UK by
the same author [52, 53] (Table 4).
Seven patients with early DD according to Shaw stages
1 and 2 [57] were identified in a study of 25 patients
[52]. Radiotherapy treatment was based on the premise
that histological changes in DD could be compared to
keloid formation so that the mitotic cycle of fibroblasts
could be interrupted with radiotherapy, resulting in a re-
duced matrix deposition. Patients were treated with a
total dose of 3000 rads (30 Grays (Gy)) gamma radiation
fractioned over 8 days. Outcomes were evaluated by as-
sessment of softening of nodules, reduction in paresthesia
and increase in finger movement. Results were presented
as 1 of 4 categories indicating the degree of functional im-
provement ranging from ‘no change’ to ‘full functional re-
covery’. No data were given for finger movement or detail
of clinical assessment of nodules and paresthesia. Full
functional recovery was reported in 6 patients and no
change in 1 patient. The follow-up period ranged between
2 and 10 years. These results were re-presented along with
new data for 3 patients with early disease (Shaw stage 1)
in a study of 18 patients treated with medium voltage
X-ray treatment over a shorter period in a later publi-
cation by the same author [53]. A total of 1500 rads
(15 Gy) was administered in 3 fractions over 5 days,
with ‘full functional recovery’ reported for 2 patients
and ‘functional improvement’ for 1 patient. The method
of assessment was not given.
Thirty two patients with early DD defined as having
no contractures from a larger cohort of 36 patients were
treated with a total dose of between 2400 and 3200 rads,
equivalent to 24–32 Gy [45]. Radiation therapy was ad-
ministered in 2 daily doses of 400r (4 Gy), repeated at
8 week intervals and patients were reassessed to 5 years
after treatment. Outcomes were based on the consistency
of the nodules. Improvement of 26 of the 32 patients was
reported and disease progression arrested in the remaining
6 patients.
Four studies [14, 47, 49, 51] employed the same
radiotherapy regime of 3 Gy daily for 5 days, repeated
after a 6 week period. Patients were identified with
early disease at baseline by modified Tubiana stage N,
N/1 and 1 [14, 47], Tubiana stage N,1 [51] or Iselin
grade1 [49]. Results were presented as ‘regression’,
‘halted/stable condition’ or ‘progression’ [14, 47, 49]
or by describing clinical findings after treatment [51].
Weinzierl [49] reported treatment with radiotherapy
of 34 hands. Outcomes were assessed by clinical
evaluation of nodule size and consistency at 7 years
after treatment. Regression was observed In 3 hands,
14 had no change and 17 progressed. The same au-
thor reported a subsequent cohort of 22 hands who
received once weekly injections of 8–13 mg of an en-
zyme, superoxide dismutase, into the affected area for
12 weeks. At 3 years 7 hands regressed, 9 had no
change and 6 progressed. A study of 156 hands from
a larger cohort of 176 hands in 99 patients [47] re-
ported regression in 18 hands, no change in 79 hands
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Study type Level of evidence (OCEBM)
Prospective (P) Retrospective
(R) Not stated (N)
Outcome measure Results Recurrence Adverse events
Improved No change Deteriorated
Keilholz (1996) [14]
Radiotherapy
(142 hands) (129 hands) Case series 4 (R) Clinical assessment
of consistency and
size of nodule









26 6 0 Not reported Not reported
Hesselkamp (1981)
[46] Radiotherapy
46 46 Case series 4 (N) Clinical assessment of
softening of nodules
and cords
24 19 3 Not reported 63 % dry skin
with desquamation,










N (n = 13), >20 %
N/1 (n = 13), 65 %
stage 1 (n = 30.
For total cohort










29 (33 hands) 29 (33 hands) Case series 4 (N) Clinical assessment
of softening of DD
tissue




Radiotherapy n = 34
39 (56 hands) 39 (56 hands) 2 Case series 4 (N) Clinical assessment
of consistency and
size of nodules




dismutase n = 22










8 3 0 Not reported Temporary skin rash
and epidermolysis





6 (4 hands) 3 (4 hands) Case series 4 (N) Clinical assessment
whether nodule size
and hardness





















Table 4 Summary of results of radiotherapy treatment (Continued)
Finney (1953) [52]
Radiotherapy
25 7 Case series 4 (N) Clinical assessment
of functional
improvement









18 3 Case series 4 (N) Clinical assessment
of functional
improvement









12 months in 2
cases.
Summary of results of radiotherapy treatment for each study, including the number of patients with Dupuytren’s disease in the total cohort in each study, the number of patients with early disease within the total
cohort, study type and design, level of evidence according to the Oxford Centre for Evidence Based Medicine (OCEBM) criteria, the outcome measure used and results. The number of hands (in brackets) is stated
when availabl, with recurrence and adverse events where stated












and progression in 59 hands, 27 within and 32 out-
side the radiotherapy field when followed up at 7 to
18 years after treatment. Results were reported
according to disease stage and also assessed by the
degree of digital contracture, although data for this
outcome were not given.
A retrospective series compared nodule size and
consistency before and after radiotherapy in different
Tubiana stages [14]. From a larger cohort of 142 hands
with DD, 129 hands with early DD graded as N, N/1 or
1 were identified. Two independent clinical assessors
evaluated the dimensions of the nodules and their
consistency. Finger flexion deformities were measured
with a protractor, although data were not given. At
3 months, 10 of 129 hands showed an improvement in
grade, and 2 hands were downgraded. Nodule size was
reported to have reduced and palpable nodules and
cords became softer in 102 of 129 hands. At long term
follow-up at a mean of 6 years (range 1 to 12 years), data
were only presented for the whole cohort with no sub-
analysis of patients with early DD.
A more recent study of a series of 3 patients with early
DD was presented in a cohort comprising a further 3 pa-
tients with plantar disease [51]. Outcomes were based
on the clinical assessment of size and consistency of
nodules or lesions, pain or discomfort and restriction of
movement. Decrease in nodule size was reported in 1
patient and flatter, softer nodules with reduced discom-
fort for 1 patient. A reduction in nodule size was re-
ported in the third patient who had bilateral disease but
no comment regarding the movement limitation noted
at baseline.
Radiotherapy was combined with plesiotherapy, a type
of superficial radiotherapy, and vitamin E in a study of
10 patients (11 hands) with Iselin stage 1 and 2 DD [50].
Outcomes were assessed at 6 months to 1 year after
treatment by clinical examination of nodule consistency
and by DD grade progression. Radiotherapy of 7,500 to
800 rads (7.5 to 8Gy) fractioned in 5 sessions and 1 cycle
of plesiotherapy of 2400 or 2500 rads (2.4 to 2.5 Gy) was
supplemented by ‘prolonged’ vitamin E although no dose
or method of administration was given. Improvement
was reported in 8 hands and no change in 3. Radiother-
apy totaling 20 Gy fractionated daily or 3 times weekly
was administered in 29 patients (33 hands) with Iselin
grade 1 DD (Kohler). Seven hands were reported was
having improved, ‘no change’ in 20 hands and ‘progres-
sion’ in 6 hands, although the assessment of outcome
and the follow-up period was not clear. Hesselkamp [46]
followed up 36 patients between 1964 and 1979 graded
Iselin grade 1 DD at between 1 to 9 years after radio-
therapy treatment. Patients received 2 series of 3 to 5
treatments of 400 rads (4 Gy). Results were categorized
as ‘better’ (24 patients), ‘no change’ (19 patients and
‘worse’ 3 patients based on clinical examination of soft-
ening of nodules and cords.
Adverse events were reported by 8 of the 10 radiother-
apy studies, with 2 reporting early DD cases [46, 49] and
6 reporting for total cohorts [14, 47, 50–53]. In 34 pa-
tients with early DD, ongoing dry skin was seen at 7 year
follow-up in 32 % [49] and at 1–9 year follow-up of 46
patients in 62 % [46], with the latter also reporting skin
atrophy, depigmentation and telangiectasia in 24 % of
patients. Grade 1 or ‘mild’ reactions were reported in 3
studies [50–52] although numbers affected were not
given. More severe 2nd degree reactions with severe
paresthesia were reported as “the rule” in 1 study of
medium voltage X-ray treatment [53] persisting in 2 of
34 patients for up to a year before resolving. Keilholz
[14] reported grade 1 acute mild skin reactions in 43 %
and grade 2 radiodermatitis in 9.8 % of the total cohort
of 142 hands, with ‘most patients’ describing itching and
burning sensations during treatment. Within the irradi-
ated area minor long term radiogenic skin and subcuta-
neous changes were seen in 77 % hands, comprising
64 % with dry skin and increased desquamation and
13 % mild skin atrophy with ‘slight fibrosis’ or occasional
telangiectasia. At a median of 10 years following treat-
ment dry skin with strong desquamation was reported in
44 (25 %) of 170 hands and subcutaneous atrophy in 15
(8.5 %) hands [47].
Discussion
There are a range of treatments available for patients
with advanced DD with digital contractures, including
surgical excision of the diseased tissue, percutaneous
needle fasciotomy and collagenase injection. However
they all suffer from disadvantages. The ideal would be a
treatment that prevents progression in the 30–50 % [5,
6] of at risk patients with early DD. A variety of treat-
ments have been proposed for early DD but there is cur-
rently no clear evidence for their role and efficacy. This
systematic review attempts to address this issue. How-
ever, it is clear that the evidence base is very weak, with
all relevant studies identified as level 4 or 5 rated ac-
cording to OCEBM and with a high risk of bias so that
results of treatment are difficult to interpret. The high
risk of bias in observational studies is due to a number
of factors, particularly lack of control treatment, retro-
spective or unclear design and assessor bias, especially
in small cohorts of patients. Publication bias, the in-
creased likelihood of authors to write up positive results
and of journals to publish positive results introduces fur-
ther risk.
Pharmacological therapy
Steroids are known to reduce inflammation which prob-
ably precedes all types of fibrosis [58]. Recent studies
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support the concept of DD as a localized inflammatory
disorder [11, 58]. Three studies reported improvement
following treatment with intralesional steroid injection
[31, 33, 34] using subjective outcomes. The treatment
appeared comparatively safe and the reported adverse ef-
fects were relatively transient. Within the limitations of
the methodology the results would appear to be encour-
aging. However, there are severe limitations of the
assessment methodology in these studies. Objective
blinded trials are required before this potentially useful
treatment can be recommended. Systemic steroids ap-
pear to be of no benefit and there are very limited data
for the efficacy of topical application.
The 3 studies examining the effect of vitamin E ad-
ministered orally gave conflicting results and there is in-
sufficient evidence to support the use of vitamin E for
the treatment of early DD.
The favourable outcome reported in the single case re-
port utilizing hyperbaric oxygen is insufficient to support
the use of this modality given the substantial clinical re-
sources and clinical burden involved. The positive re-
sults of topical aminosyn, an amino acid solution, with
ultrasound in 22 patients [38] are confounded by the
study also reporting inconclusive results for ultrasound
and positive results for aminosyn alone with small num-
bers of patients. Injection with furazolidone [37] is not
recommended as it has been banned from use in
humans and animals in the USA and European Union
amid concerns as a potential carcinogen.
Physical therapy
Physical therapy studies were the most robustly assessed,
using objective physical measures of digital joint exten-
sion [40–44], hand span and grip strength [40]. Al-
though a trend towards digital extension improvement
was seen, sample sizes were small and the evidence to
support the use of physical therapies very limited and
inconclusive.
One study attempted to objectively evaluate changes
in subcutaneous features of DD using ultrasound im-
aging to monitor treatment outcome, but failed to detect
change at 8 weeks following treatment [43]. Ultrasound
imaging has been used to identify DD in the hand [59]
but has not been used to examine change over longer
periods and research to assess the feasibility of using
ultrasound imaging for this purpose may be useful in fu-
ture studies.
Radiotherapy
Radiotherapy is believed to reduce the development of
myofibroblasts [14, 52], although the precise mechanism
of action remains unclear [60]. A number of publications
reporting radiotherapy treatment for early DD could not
be included for review as it was not possible to extract
data for early DD patients from the total cohort accord-
ing to the review criteria and studies including patients
who had previously received other interventions (see
Additional file 2).
Ten radiotherapy studies met the inclusion criteria.
The studies were limited by a lack of quality, with no
blinding or randomization and the use of subjective out-
come measures. Participant numbers were small (10 or
less) in 4 of the 10 studies [50–53]. Of the remaining 6
studies 2 reported improvement [14, 45], 3 were equivo-
cal [46, 47, 49] and 3 showed no change [48]. Weinzierl
noted that results in his study did not differ clearly from
the natural history of early DD [49].
Toxicity should be considered when using radiother-
apy for a benign disorder. Toxicity was recorded accord-
ing to European Organization Research and Treatment
of Cancer (EORTC) criteria [61] by one study [14] or
LENT-SOMA criteria [47], although sub analysis accord-
ing to the grade of DD was not reported. At a mean
follow-up of 6 years (range 1–12) of the total cohort of
142 hands (96 patients) reported by Keilholz, 61 hands
(43 %) developed grade 1 reactions and 14 Grade 2 reac-
tions with pronounced erythema and moderate edema
[14]. No Grade 3 or 4 reactions were observed. Over a
median 10 year follow up (range 7–18 years), 44 hands
developed significant desquamation and 15 subcutane-
ous atrophy and telangiectasia [47]. Six further studies
reported acute and long term effects. Toxicity was not
reported in 2 studies [45, 48]. In the UK, The National
Institute for Health and Care Excellence (NICE) advises
that there is limited evidence regarding the safety of ra-
diation therapy for early DD but does not raise any ser-
ious safety concerns. However, there is a theoretical risk
that patients could develop radiation induced cancer in
the long term [60].
There were inconsistencies in the definition of early
disease in studies reporting the efficacy of radiotherapy.
Early disease was defined as without contractures in one
study [45], whereas data for patients with Tubiana stages
2 and 3 i.e. a total flexion contracture of between 45 and
135°, were included in other studies of early DD [14, 47],
although it was possible to separately analyse the data
for patients with less severe contractures.
Collagenase
The use of clostridial hystolyticum collagenase injection
was not included in the review as the Food and Drug
Administration (FDA) approval [62] was given for use in
adult patients with advanced DD. More recent studies
reporting results of collagenase injection have included
patients with early disease as defined as a palpable cord
with up to 30° of digital contracture [63–68]. However,
the role of collagenase in early DD has been questioned
as the safety and efficacy of collagenase injection for
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early disease was not included in the original submission
to the FDA that led to the approval of collagenase
flexion deformities greater than 20° [69].
Limitations of the review
Identifying the efficacy and safety of non-surgical treat-
ments for patients with early DD in this review was
challenging due to the poor quality of studies, small
numbers of participants in many studies and the variable
definitions of early disease and disease progression. Add-
itionally, limited details on study methodology made
evaluation difficult.
Eleven of the 19 case series described results for less
than 10 early DD patients [18, 33, 34, 40–42, 44, 50–53]
and are unlikely to have been adequately powered to
permit conclusions. Only 4 studies described results for
cohorts of early DD patients [31, 46, 48, 49] as defined
by the criteria of this review. The remaining studies in-
cluded early DD patients within cohorts of patients with
more advanced disease or were case studies.
The search terms were selected to be inclusive but it is
possible that some studies were not found by our review.
The use of Tubiana grading to define the severity of DD
by some studies resulted in the inclusion of patients with
total digital contractures of up to 45° in the analysis. It
could be argued that this represents patients with rela-
tively advanced DD. However the total digital flexion
calculation used by Tubiana classification could relate to
2 or 3 mildly contracted joints, although it could equally
apply to 1 more severely affected joint, with other joints
unaffected. This highlights the problems associated with
this type of grading.
Clinical assessment of size and consistency of nodules
and cords was used as an outcome measure in a number
of studies [14, 30–34, 45, 46, 48–51]. However, it may be
difficult to ascribe nodule resolution to treatment as
nodules have been reported to regress spontaneously.
An epidemiological study conducted in Iceland reported
that of 56 men initially noted to have nodules or cords,
8 were judged to have normal hands 18 years later [5].
The variation in diagnostic criteria for DD has been
noted [3, 70]. It has been suggested that 2 types of DD
exist, typical (progressive) and atypical (non-progres-
sive), with typical disease often progressing to require
surgical intervention whilst treatment is rarely indicated
for atypical DD [71]. Each type may produce a different
response to treatment. More recently fluctuation in the
course of early DD has raised uncertainty about the nat-
ural history of DD [7].
Conclusions
Given the limitations of treatments available for ad-
vanced digital contractures, the ideal treatment for pa-
tients with progressive DD would be at the early stage to
prevent the development of flexion deformities [8]. Of
the many treatments that have been tried over the years
for early DD, only intralesional steroid injection or
radiotherapy appear to offer some benefit. The studies
reporting the effect of Intralesional steroids were con-
founded by the lack of a control group and potential as-
sessor bias. The literature is divided on the efficacy of
radiotherapy and effect on the course of early DD with
some showing it is efficacious but others demonstrating
little or no benefit. Unfortunately there is lack of object-
ive evidence for efficacy of either intralesional steroid in-
jection or radiotherapy and there is an urgent need for
adequately powered double blinded randomized trials.
Disease recurrence following treatment is infrequently
reported in the reviewed studies. It is not clear how long
recurrence should be monitored but a study of intrale-
sional steroid injection [31] suggests that this may need
to be in excess of 3 years.
For future studies investigating the effectiveness of
non-surgical treatments of early DD, we would recom-
mend the following:
 A clear definition of early DD and a consensus on a
definition of disease recurrence is also essential to
allow comparison between studies.
 All treatment outcomes should be measured using
objective, reproducible methods, including:
1. Goniometric measurement of extension and
flexion of individual joints.
2. A reliable and validated measure of nodule
consistency and the role of tonometry, which has
been used to assess Dupuytren’s pre-and
post-surgery [72], should be investigated.
3. The use of ultrasound imaging to monitor change
in nodule size.
4. New disease specific Patient reported outcome
measures (PROMs). These need to be developed to
gain the patient’s perspective in early disease and to
monitor disease progression. PROMS have been
developed and validated in advanced disease but
these are unlikely to reflect the problems of
patients with nodules with little or no contracture.
 Studies should be well designed and adequately
powered.
 Safety should be reported and described in all
studies.
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